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Abstract
Background: Postpartum hemorrhage is the leading cause of maternal mortality in low- and middle-income
countries. While evidence on uterine balloon tamponade efficacy for severe hemorrhage is encouraging, little is
known about safety of this intervention. The objective of this study was to evaluate the safety of an ultra-low-cost
uterine balloon tamponade package (named ESM-UBT) for facility-based management of uncontrolled postpartum
hemorrhage (PPH) in Kenya and Sierra Leone.
Methods: Data were collected on complications/adverse events in all women who had an ESM-UBT device placed
among 92 facilities in Sierra Leone and Kenya, between September 2012 and December 2015, as part of a multi-
country study. Three expert maternal health investigator physicians analyzed each complication/adverse event and
developed consensus on whether there was a potential causal relationship associated with use of the ESM-UBT
device. Adverse events/complications specifically investigated included death, hysterectomy, uterine rupture,
perineal or cervical injury, serious or minor infection, and latex allergy/anaphylaxis.
Results: Of the 201 women treated with an ESM-UBT device in Kenya and Sierra Leone, 189 (94.0%) survived. Six-
week or longer follow-up was recorded in 156 of the 189 (82.5%). A causal relationship between use of an ESM-UBT
device and one death, three perineal injuries and one case of mild endometritis could not be completely excluded.
Three experts found a potential association between these injuries and an ESM-UBT device highly unlikely.
Conclusion: The ESM-UBT device appears safe for use in women with uncontrolled PPH.
Trial registration: Trial registration was not completed as data was collected as a quality assurance measure for
the ESM-UBT kit.
Keywords: Uterine balloon tamponade, Postpartum hemorrhage, Maternal mortality, Maternal health, Developing
countries
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Background
Postpartum hemorrhage (PPH) is the leading cause of
maternal mortality in low- and middle-income countries.
Although reduction of maternal mortality has been a
worldwide focus since 1990, a recent World Health
Organization report on progress from 1990 to 2015
described that PPH-associated mortality remains unaccept-
ably high, with 54,000 deaths in sub-Saharan Africa in 2015
alone [1, 2]. The majority of these deaths could have
been averted with timely access to quality emergency
obstetric care [2, 3].
First-line treatment for PPH includes administration of
uterotonic agents. When hemorrhage persists, if available,
alternative methods may be employed, including uterine
balloon tamponade (UBT), non-pneumatic anti-shock
trousers, and surgical interventions such as uterine artery
embolization, B-Lynch compression sutures, and ultim-
ately hysterectomy. In low-resource settings, access to sur-
gical services is limited or non-existent, thus women with
uncontrolled hemorrhage often die. Until recently, UBT
devices were unavailable in these regions [2–4].
Over the past 7 years our team has designed, developed,
implemented, and refined a PPH evidence-based package
utilizing an ultra-low-cost condom-based uterine balloon
called Every Second Matters for Mothers and Babies–
UBT (ESM-UBT) [5–8]. When compared with commer-
cially available devices, ESM-UBT utilizes readily available
low cost materials (Fig. 1). Data have been collected dem-
onstrating efficacy of the package in arresting PPH and
averting emergency hysterectomy [5–8]. The ESM-UBT
package has been successfully implemented across all levels
of the health systems in South Sudan, Kenya, Tanzania, Si-
erra Leone, Senegal, Zambia, Ghana and Nepal.
While the data to date support a high degree of
efficacy of the ESM-UBT package in arresting uncon-
trolled PPH, with 98% survival overall, a critical and in-
complete part of the equation defining overall impact is
understanding the safety profile of the ESM-UBT device
[6]. To date there have been limited follow-up data on
the safety of UBT devices. A study from India followed
18 patients for 6 weeks after condom catheter tampon-
ade placement and reported no complications [9]. An-
other report described 31 women who were followed for
4 months and longer after Rusch UBTs were placed, and
also found no UBT-associated complications [10].
In this study, our goal was to better understand
the safety profile of the ESM-UBT device by follow-
ing all women who presented to our Kenya and
Sierra Leone ESM-UBT facilities in whom an ESM-
UBT device was placed for uncontrolled PPH.
Methods
All women were enrolled who had an ESM-UBT device
placed between September 2012 and December 2015,
among the 92 facilities active with the ESM-UBT pack-
age in Kenya and Sierra Leone. Facilities were defined as
active when 85% or more of their skilled birth attendants
trained in ESM-UBT, ESM-UBT wall charts were
mounted in each delivery area, and ESM-UBT manuals
and devices were readily available. Data on improvised
UBT kits placed by providers not trained on the ESM-
UBT protocol were not included in this analysis (com-
pared to our previous analysis on UBT efficacy) [6]. The
UBT device was used within the context of the estab-
lished national protocol for management of PPH when
all other methods (including active management of the
third stage of labor, emptying of the bladder, breastfeed-
ing, administration of uterotonics, and manual removal
of the placenta and blood clots) failed [6]. The ESM-
UBT clinical pathway recommends a single dose of anti-
biotics, of the provider’s choice, to be administered after
placement of an ESM-UBT device.
Data on adverse events/complications were collected
via a multi-pronged approach to include telephone and
Fig. 1 The ESM-UBT kit. Kit contents include: illustrated checklist,
data collection card, cotton string, luer-lock syringe, condoms, and a
size 24 urinary catheter. Source: Division of Global Health and Human
Rights, Department of Emergency Medicine, Massachusetts General
Hospital, Boston, MA, USA
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in-person interviews with patients, village chiefs and
community health workers; review of health facility
records; and examination of data cards included in each
of the ESM-UBT device kits. After a provider placed a
UBT, the UBT provider filled out a data card and con-
tacted the study coordinator. The study coordinators
then visited the UBT facility to verify the data, formally
interviewed the UBT provider and compared the data
card with the patient’s chart. The data collection cards
documented the kit tracking number, facility name,
delivery date and time, interventions performed prior to
UBT placement, mental status and vital signs at the time
of UBT placement, effectiveness of hemorrhage control,
steps taken after UBT placement, need for maternal re-
suscitation or transfusion, and adverse events. Adverse
events/complications specifically sought included death,
hysterectomy, uterine rupture, perineal or cervical
injury, serious or minor infection, and latex allergy/ana-
phylaxis. Data were collected prospectively for the time
interval between delivery and facility discharge through-
out the entire study time period. Adverse events/compli-
cations data collection was extended to include follow-
up at two and 6 weeks following facility discharge,
beginning in October 2014. The field data collection
team conducted formal follow-up interviews of UBT
providers and mothers who had undergone UBT place-
ment. Six-week or longer follow-up data were collected
retrospectively for women who had an ESM-UBT device
placed prior to October 2014. Three expert maternal
health investigator physicians (AR, ME, and TB) ana-
lyzed each complication/adverse event and deliberated
on whether there was a potential causal relationship
associated with use of the ESM-UBT device. The three
experts were instructed to err on the side of attributing
possible causality if there was doubt in certainty. In
cases of disagreement the three were asked to discuss
and arrive at consensus on categorization.
Descriptive data analysis was performed utilizing Micro-
soft Excel 2015 (Seattle, WA, USA) and STATA 13.1 (Col-
lege Station, TX, USA). This study was approved by the
institutional review board of Partners HealthCare (Massa-
chusetts General Hospital, Boston, MA, USA), the ethical
review committee of Maseno University School of Medi-
cine (Maseno, Kenya) and the Office of the Sierra Leone
Ethics and Scientific Review Committee (Ministry of
Health and Sanitation of Sierra Leone). Verbal informed
consent was obtained in each case.
Results
Among the 92 ESM-UBT active facilities, 201 women
were treated with an ESM-UBT device for uncontrolled
PPH in Kenya (154, 76.6%) and Sierra Leone (47, 23.4%)
between September 2012 and December 2015. One-
hundred and eighty-nine (94.0%) of the 201 women
survived. All 201 women had their ESM-UBT devices
placed at a health facility and 146 (76.0%) of 192 by a
midlevel provider (clinical officer, midwife, nurse, or
aide). One hundred and fifty-six (77.6%) of the 201 re-
ceived a single dose of prophylactic antibiotics. The
mean ages were 27.1 years in Kenya and 25.8 years in Si-
erra Leone. The median number of prior pregnancies
was 2.0 in both countries. Thirty-nine (25.0%) of the
hemorrhaging women in Kenya and 22 (46.8%) in Sierra
Leone met criteria for advanced shock. Six (3.0%) of the
201 deliveries were via cesarean section (Table 1).
Adverse events/complications between delivery and
facility discharge
All 12 maternal deaths in which ESM-UBT devices were
placed occurred prior to facility discharge, and each case
underwent detailed review by the respective ministries
of health (county level in Kenya and national in Sierra
Leone), by each of the facilities’ internal processes and
by our own research team (Table 2). Nine (75.0%) of the
12 women who died were unconscious due to advanced
hemorrhagic shock at the time the ESM-UBT device
was placed and were not able to be resuscitated. One (8.
3%) of the 12 maternal deaths was septic at the time of
delivery with a fever of 40 degrees Celsius. She did not
receive prophylactic nor treatment antibiotics, was found
to have disseminated intravascular coagulopathy imme-
diately after delivery, and died within an hour subse-
quent to delivery. Another woman (8.3%) had been
hospitalized and treated for severe malaria over the week
prior to the onset of her labor. Although the ESM-UBT
device arrested a brief high-volume PPH and she
received a single dose of prophylactic antibiotics, she
was found dead during the early morning, 26 h after ces-
sation of her hemorrhage. One (8.3%) of the maternal
deaths was described as precipitous and the reported
cause of death was “pulmonary embolism.”
One hundred and eighty-four (97.5%) of the 189
women who survived uncontrolled PPH had data re-
corded on adverse events/complications for the time
interval between delivery and facility discharge (Table 3).
Three (1.6%) of the 184 had a perineal or cervical injury:
specifically, one (0.5%) had a “vulvo-vaginal laceration,”
one (0.5%) had a “vaginal hematoma,” and one (0.5%) a
“cervical laceration.” All three injuries were successfully
repaired, and all three injuries were considered by the
skilled birth attendants who performed the deliveries
to have been caused by birth trauma and not the
ESM-UBT device.
One (0.5%) of the 184 underwent hysterectomy (un-
clear reasoning since hemorrhage reportedly had been
arrested) and none experienced uterine rupture, serious
or minor infection, or latex allergy/anaphylaxis in the
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time interval between ESM-UBT device placement and
facility discharge.
Expert review of the adverse events and complications
in the interval between delivery and facility discharge
agreed that although unlikely, one of the twelve deaths
(pulmonary embolism) and the three perineal injuries
could have been related to use of the ESM-UBT device.
No other adverse events potentially caused by an ESM-
UBT device were thought to have occurred during this
time interval.
Adverse events/complications between facility discharge
and 6 weeks post-delivery
One hundred and fifty-six (82.5%) of the 189 women
who survived uncontrolled PPH subsequent to ESM-
UBT device placement were followed for at least 6 weeks
post-discharge (Table 4). Thirty-two (16.9%) women
were lost to follow-up and one (0.5%) declined to par-
ticipate. Three (1.9%) of the 156 experienced an adverse
event/complication during the time interval between
facility discharge and 6 weeks post-delivery. Two (1.3%)
of the 156 reported minor infections over these 6 weeks.
Both women had received a single dose of prophylactic
antibiotics. One of these women labored for 15.5 h prior
to cesarean section, after which an ESM-UBT device
was placed for uncontrolled hemorrhage. Two weeks
after delivery, she was diagnosed with and successfully
treated for “mild endometritis.” The second woman was
successfully treated with antibiotics for an “episiotomy
wound infection,” diagnosed 2 weeks after delivery. Both
women were successfully treated with antibiotics as out-
patients and neither had signs of sepsis. One woman (0.
6%) underwent hysterectomy 1 month after ESM-UBT
placement due to “continued bleeding.”
Review of the adverse events and complications in the
interval between facility discharge and 6 weeks post-
delivery agreed that the one case of endometritis could
have been associated with use of the ESM-UBT device.
Table 1 Demographics of women receiving ESM-UBT device
Kenya Sierra Leone Total
Patients (%) 154 (76.6) 47 (23.4) 201
Age, mean (range) 27.1 (16–44) 25.8 (16–41) 26.8 (16–44)
Prior pregnancies, median (range) 2 (0–13) 2 (0–7) 2 (0–13)
Prior deliveries, median (range) 2 (0–13) 2 (0–7) 2 (0–13)
Living children, median (range) 2 (0–13) 2 (0–5) 2 (0–13)
Location of delivery, n (%):
Home 17/146 (11.6) 0 (0.0) 17/193 (8.8)
Facility 129/146 (88.4) 47 (100.0) 176/193 (91.2)
Level of provider placing UBT, n (%)a:
Total 145/192 (75.5) 47/192 (24.5) 192
Doctor 43 (29.7) 3 (6.4) 46 (24.0)
Clinical officer/ clinical health officer 16 (11.0) 4 (8.5) 20 (10.4)
Midwife 86 (59.3) 12 (25.5) 98 (51.0)
State-controlled community health nurse N/A 10 (21.3) 10 (5.2)
Maternal child health aide N/A 18 (38.3) 18 (9.4)
Mode of delivery, n (%):
Vaginal delivery 148/154 (96.1) 47 (100.0) 195/201 (97.0)
Cesarean section 6/154 (3.9) 0 (0.0) 6/201 (3.0)
a Kenya designations: doctor, clinical officer, nurse. Sierra Leone designations: doctor, clinical health officer, midwife, state controlled community health nurse,
maternal child health aide
Table 2 Causes of death among women in whom ESM-UBT devices were placed
Kenya, n (%) Sierra Leone, n (%) Total, n (%)
Maternal deaths 6 (3.9) 6 (12.8) 12 (100.0)
Hemorrhagic shock 4 (2.6) 5 (10.6) 9 (75.0)
Sepsis 1(0.6)a 1(2.1)a 2 (16.7)
Possible pulmonary embolism 1 (0.6) 0 (0.0) 1 (8.3)
a Sepsis symptoms were evident prior to delivery in both cases
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No other adverse events potentially caused by an ESM-
UBT device were reported during this time interval.
Discussion
While efficacy of the ESM-UBT package has previously
been reported, this investigation aimed to examine the
safety of the ESM-UBT device [5–8]. Of the 201 women
treated with an ESM-UBT device in this study, 189 (94.
0%) survived, of which in-facility safety data were avail-
able for 184 (97.4%) and six-week follow-up in 156 (82.
5%). Immediate postpartum, in-facility adverse outcomes
and complications included 12 (6.0%) deaths, three (1.
6%) of 184 that experienced perineal or cervical injuries
and one (0.5%) of 184 that underwent hysterectomy. In
the 156 women for whom follow-up data between facil-
ity discharge and 6 weeks post-delivery were available,
two (1.3%) experienced minor infections and one (0.6%)
underwent hysterectomy.
Nine (75.0%) of the 12 women who died were in
advanced hemorrhagic shock at the time of ESM-UBT
device placement and two were septic (one from mal-
aria) prior to delivery (Table 2). The ESM-UBT device
appeared to play no role in the deaths of these 11
women. Although seeming unlikely, the three experts
thought that it was not possible to exclude a potential
association between the one precipitous death that was
assigned pulmonary embolism (no autopsy performed)
and the use of the ESM-UBT device.
Hemorrhagic shock remains the number one killer of
pregnant women in the world today, accounting for as
many as 130,000 deaths annually [11]. Among the nine
hemorrhagic shock deaths in this study, the consistent
theme was very late attempts at intervention. Septic
shock occurs in 0.002–0.01% of all deliveries worldwide
and accounts for 12–13% of maternal deaths in the
United States [12–14]. While an ESM-UBT device could
conceivably contribute to infection and sepsis since it in-
volves introduction of a foreign body into the uterus,
neither of the maternal deaths from sepsis in this study
appeared related to the ESM-UBT device, given that
symptoms clearly preceded device placement. Overall, of
the 156 women who were followed for at least 6 weeks,
no cases of ESM-UBT-associated sepsis were identified.
In highly resourced settings, pulmonary embolism has
an overall incidence in pregnancy of one per 7000 and
has been described responsible for 9–10% of maternal
deaths [12, 13]. However, in low resource poor settings,
without autopsy and/or advanced imaging, diagnostic
certainty regarding pulmonary embolism is low; thus
causation from the ESM-UBT device cannot be
entirely eliminated.
The baseline incidence of delivery-associated severe
vaginal lacerations is 4–5%, perineal hematomas 0.1–0.
3%, and cervical lacerations 0.2% [13, 15–17]. The find-
ing of three (1.6%) perineal injuries among the 184
women who received ESM-UBT devices in our study
was a lower rate than what would have been expected in
the general population of women who deliver. Addition-
ally, our skilled birth attendants and our three experts
felt certain that the ESM-UBT device did not cause
these three perineal injuries.
Two women (1.0%) in our study underwent non-
emergency hysterectomy subsequent to ESM-UBT place-
ment, however, neither appeared related to ESM-UBT
device use. In fact, the hysterectomy rate in this popula-
tion of 201 women with uncontrolled PPH was low com-
pared to expected rates of 3.8–35.0% [9, 10, 18–21]. These
findings further supported our previously reported find-
ings on the ability of ESM-UBT to avert hysterectomy [8].
During the six-week follow-up period, two women (1.
3%) were noted to have minor infections despite having
been administered a single dose of prophylactic antibi-
otics. One was diagnosed with mild endometritis and
one an infection of her episiotomy site. It was unlikely
that the ESM-UBT device contributed to the episiotomy
wound infection, but, quite possible, despite her pro-
longed labor and cesarean section, that use of the ESM-
UBT device contributed to the one case of suspected
endometritis. At baseline, endometritis is diagnosed after
1–3% of vaginal deliveries and is ten times more com-
mon following cesarean section [22]. In our series of 156
women followed out to 6 weeks, the one (0.6%) case of
Table 3 Adverse events among PPH survivors, between delivery
and discharge
Kenya, n (%) Sierra Leone, n (%) Total, n (%)
Total cases 148 (78.3) 41 (21.7) 189 (100)
Data not available 5/148 (3.4) 0/41 (0.0) 5/189 (2.6)
Hysterectomy 1/143 (0.7) 0/41 (0.0) 1/184 (0.5)
Uterine rupture 0/143 (0.0) 0/41 (0.0) 0/184 (0.0)
Perineal or cervical injury 3/143 (2.1) 0/41 (0.0) 3/184 (1.6)
Serious infection 0/143 (0.0) 0/41 (0.0) 0/184 (0.0)
Minor infection 0/143 (0.0) 0/41 (0.0) 0/184 (0.0)
Latex allergy/anaphylaxis 0/143 (0.0) 0/41 (0.0) 0/184 (0.0)
Table 4 Adverse events among PPH survivors between
discharge and six-week follow-up
Kenya, n (%) Sierra Leone, n (%) Total, n (%)
Total cases 148 (78.3) 41 (21.7) 189 (100)
Lost to follow-up 32 (21.6) 0 (0.0) 32/189 (16.9)
Declined to participate 1 (0.7) 0 (0.0) 1/157 (0.6)
Minor infection 2 (1.7) 0 (0.0) 2/156 (1.3)
Hysterectomy 1 (0.9) 0 (0.0) 1/156 (0.6)
Total adverse events 3 (2.6) 0 (0.0) 3/156 (1.9)
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endometritis falls below the expected baseline among
the general population of women who deliver.
This study is the largest case series to date examining
the safety of a condom UBT device. A lack of absolute cer-
tainty of the diagnoses was one of the primary limitations.
A second limitation was that the authors examined the
data and attributed causation, thus inviting potential
reporting bias. To mitigate this bias, the investigators were
intentionally inclusive in assigning potential association
and/or causation. Another limitation was the incomplete
follow-up out to 6 weeks post-delivery despite the multi-
pronged approach to data collection. Almost all women
lost to follow-up were from the nomadic tribes along the
border with Somalia, primarily in Garissa County, Kenya.
However, given that the multi-pronged data collection in-
cluded direct communication with, and interviews of,
rural community health workers and local health pro-
viders in all the settings where ESM-UBT devices were
placed, it was unlikely any deaths were missed. Another
limitation was the potential for recall bias when women
were asked to recount their experience months subse-
quent to placement of an ESM-UBT device. However, we
expected that most women would recall such injuries, in-
fections or other complications even after the passage of
time. Additionally, although it is difficult to draw causal
inferences about adverse events in a case series study de-
sign, the authors believe that a randomized controlled trial
would have been unethical.
Although it is impossible to assign causation between
ESM-UBT device placement and the adverse events with
complete certainty, it appears that, at worst, the ESM-
UBT device was associated with one death, three peri-
neal injuries, and one case of mild endometritis among
the women in this study. Since the adverse events and
complication rates were not above expected baseline in
women among the general population of deliveries, and
since most of the potential associations between these
adverse events and the ESM-UBT device were not likely,
it appears that the risk of ESM-UBT device-associated
harm is low when used in women with uncontrolled
PPH. In this case series, the ESM-UBT device appears
safe for use in women with uncontrolled PPH.
Conclusion
In this case series, the ESM-UBT device appears safe for
use in women with uncontrolled PPH. Future studies on
UBT should seek to further define harm versus benefit
and optimal use characteristics, clarify the role of antibi-
otics, develop models for sustainability and scale, and
identify additional opportunities for ending maternal
death and disability from PPH.
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